The largest database of trusted experimental protocols

Pmir report β gal

Manufactured by Thermo Fisher Scientific
Sourced in United States

The PMIR-REPORT β-gal is a lab equipment product designed to measure and quantify β-galactosidase (β-gal) activity. It functions by providing a colorimetric or fluorometric method to detect and analyze β-gal levels in various biological samples.

Automatically generated - may contain errors

3 protocols using pmir report β gal

1

Luciferase Assay for Smad7 3'UTR

Check if the same lab product or an alternative is used in the 5 most similar protocols
Smad7 mRNA 3′-UTRs containing one miR-21-binding sequence for the mouse Smad7 gene (NCBI reference sequence: NM_001042660.1) were acquired by oligonucleotide synthesis following the manufacturer's instructions (pMIR-REPORT™ System, miRNA Expression Reporter Vector, Part No. AM5795, Ambion, Shanghai, China) (Table III). The annealing fragment was then subcloned into the SpeI site and HindIII site in the pMIR-REPORT™ miRNA expression reporter empty vector (Ambion, Shanghai, China). Binding-region mutations were achieved using an oligo synthesis following the manufacturer's instructions (Ambion). Transient transfection into HEK-293 cells (1×104 cells/well) was carried out in 24-well plates with Lipofectamine™ 2000 (Invitrogen, Shanghai, China) following the manufacturer's instructions. The cells were co-transfected with 200 ng of the luciferase construct plasmid and 50 ng of pMIR-REPORT β-gal (Ambion) plasmid, and luciferase assays were performed using the dual-luciferase reporter assay system (Ambion) according to the manufacturer's instructions. Luminescent signals were quantified using a luminometer (Promega, Madison, WI, USA), and each value from the firefly luciferase construct was normalized by β-gal assay.
+ Open protocol
+ Expand
2

Identification and Validation of PTN as miR-384 Target

Check if the same lab product or an alternative is used in the 5 most similar protocols
Using four computer algorithms, including TargetScan, miRanda, PicTar and miRGen, we identified PTN as a possible miR‐384 target. The sites were predicted based on the base‐pairings of seed‐sequence matches. To construct reporter plasmids containing wild‐type or mutant miR‐384 target sites for human PTN 3′UTR segments, oligonucleotide pairs containing the desired miR‐384 target region and restriction enzymes sites were annealed and ligated into the pMIR‐REPORT™ miRNA Expression Reporter Vector (Ambion, Grand Island NY, USA). The mutated putative miR‐384 binding site in the PTN 3′UTR was generated using a QuikChange site‐directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. These cells were plated in 12‐well plates (3 × 104 cells/well). Twenty‐four hours later, the pMIR‐PTN‐3′‐UTR construct (200 ng) and the β‐gal expression vector pMIR‐REPORT‐β‐gal (200 ng) (Ambion) were cotransfected with a miR‐384 mimic or a mimic control at a final concentration of 100 nM using Transfast™ Transfection Reagent (Promega). Twenty‐four hours after transfection, cell lysates were collected, and luciferase activity was measured according to the manufacturer's protocol. Firefly luciferase activity was normalized to β‐gal expression for each sample.
+ Open protocol
+ Expand
3

Regulation of N-myc expression by miR-17

Check if the same lab product or an alternative is used in the 5 most similar protocols
The 3′-UTR of N-myc (880 bp) was PCR-amplified (primers available upon request) and cloned into pMIR-Luciferase reporter plasmid (Ambion) using T4-ligase (Promega, Madison, WI, USA). The sequences of the inserts were confirmed (GENEWIZ, South Plainfield, NJ, USA).
SK-N-LD cells were co-transfected in quadruplicate with either pMIR-Luciferase-N-myc-UTR or pMIR-REPORT-Luciferase (Luciferase vector) and pMIR-REPORT-β-gal (Ambion) using Lipofectamine 2000. After 24 h, half of each of the co-transfected populations were treated with 100 nM of either the miR-17 inhibitor or a non-specific control oligo (both from Ambion). Twenty-four hours thereafter luciferase and β-gal activities were assessed (Promega). Luciferase activity was normalized to β-gal and expressed as a fold-change in the miR-17-inhibitor-treated cells compared to the control-treated cells for both the pMIR-Luciferase-full-N-myc 3′-UTR and the vector transfectants.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!